High Intensity Focused Ultrasound (HIFU) unit, Department of Urology, Churchill Hospital, Headington, Oxford, OX3 7LE
- Senior Clinical Scientist
- Honorary Consultant in HIFU Therapy
Professor Feng Wu received his medical training at Chongquing Medical University in China. In 1988 he began his research career in high intensity focused ultrasound (HIFU) therapy, and developed his own clinical HIFU device, with his work largely dedicated to treating solid tumors, including those of the liver, kidney, breast, pancreas, uterus, bone, and soft tissues. Until now Professor Wu and his teams have treated more than 50,000 patients, the largest population of HIFU treated cancer patients in the world.
In 2002, Professor Wu was invited to help establish the first clinical HIFU Unit in the United Kingdom, and to assist in running clinical HIFU trials for the treatment of tumour patients in Churchill Hospital, Oxford University Hospitals. His pivotal role in bringing this emerging technology to the UK has resulted in him becoming the first Chinese-trained clinician ever to be entered directly onto the specialist register in the UK - under the newly created Specialty of High Intensity Focused Ultrasound Therapy.
Professor Wu is currently working as HIFU Consultant at Oxford University Hospitals, and also serving as Senior Clinical Scientist at Nuffield Department of Surgical Sciences, University of Oxford. He has published more than 200 papers in peer-reviewed journals and seven book chapters related to HIFU therapy, and served as Editor-in-Chief in the World Journal of Surgical Procedure and Editorial Board Member in nine peer-reviewed journals. He was one of the founders for International Society for Therapeutic Ultrasound (ISTU), and was selected as Secretary-General of ISTU for six consecutive years (2001-2006). Professor Wu received the Society’s William and Francis Fry Award in 2013, and served as Honorary Symposium President for the 4th International Symposium on Current and Future Applications of Focused Ultrasound in 2014.
Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound.
Spiers L. et al, (2023), BMC Cancer, 23
Phase-shift Perfluoropentane Nanoemulsions Enhance Pulsed High-intensity Focused Ultrasound Ablation in an Isolated Perfused Liver System and Their Potential Value for Cancer Therapy.
Zhao L-Y. et al, (2022), J Ultrasound Med, 41, 107 - 121
Alterations in Immune Response Profile of Tumor-Draining Lymph Nodes after High-Intensity Focused Ultrasound Ablation of Breast Cancer Patients.
Zhu X-Q. et al, (2021), Cells, 10
Oxford's clinical experience in the development of high intensity focused ultrasound therapy.
Prachee I. et al, (2021), Int J Hyperthermia, 38, 81 - 88
Large-Volume Hyperthermia for Safe and Cost-Effective Targeted Drug Delivery Using a Clinical Ultrasound-Guided Focused Ultrasound Device.
Lyon PC. et al, (2021), Ultrasound Med Biol, 47, 982 - 997